Abstract
Background Despite of growing trends there is no consensus on types of drug for neoadjuvant chemotherapy in gastric cancer, especially between East and West. Neoadjuvant chemotherapy with docetaxel, oxaliplatin, fluorouracil and Leucovorin (FLOT) regimen has showed promising results in terms of pathological response and survival rate. However, S1 or TGO plus oxaliplatin (SOX) is more favorable chemotherapy regimen in eastern countries. We conducted this study to evaluate the safety and efficacy of both regimens.
Methods This is a prospective, open label, randomized controlled trial. Patients with locally advanced gastric cancer were 1:1 randomized to FLOT or SOX group. Patients in FLOT group received 4 cycles of FLOT chemotherapy and the patients in SOX group received 3 cycles of TGO plus oxaliplatin prior to curative gastrectomy. The primary endpoint was the comparison of complete or sub-total tumor regression grading (TRG1a+ TRG1b) in the primary tumour.
Results Altogether 74 cases enrolled between August 2018 and March 2020, all 74 randomly assigned cases were considered as intention-to-treat (ITT) population and the 55 patients who completed the planned chemotherapy and surgery were considered as per protocol (PP) population. There was no significant difference in pre-treatment clinical parameters between two groups (p>0.05). There was no significant difference of adverse effects or postoperative morbidity and mortality between two groups (p>0.05). Similarly, there was no significant difference in proportion of tumor regression grading between two groups (p>0.05). In ITT population, complete or sub-total TRG was 20.0 percent in FLOT versus 32.4 percent in SOX group (p>0.05). Conclusions: Our study demonstrates that FLOT and SOX regimens were safe in terms of toxicity and postoperative morbidity. Both regimens were similarly effective for gastric cancer patients in terms of pathological response. A large scale phase 3 randomized controlled trial is necessary for the validation of this result.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
ClinicalTrials.gov, number NCT03636893
Funding Statement
The overall costs of publication will be funded by grants from the National Natural Science Foundation of China (No. 91529302 (BY Liu), No.81772509 (Liu BY), and No. 81871904 (Zhu ZG)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
institutional review board (IRB), Ruijin Hospital
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Any data regarding this study are kept safe with corresponding authors and can be obtained for reasonable request.